Primary regulatory
TRIUMPH-1: retatrutide in participants with obesity or overweight
Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.
ClinicalTrials.govPublished 2023-07-03Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- ClinicalTrials.gov
- Source type
- Primary regulatory
- Registry ID
clinicaltrials-retatrutide-triumph1- Trial ID
- NCT05929066
Source usage
Linked from 12 pages
Video audit
Unapproved Weight-Loss Drug 'Reta' Sold Online Despite Safety Concerns
Video auditRetatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)
Video auditDr. Explains Why Retatrutide is KING of Fat Loss Peptides
Video auditPeptides: The Science, Uses & Safety | Dr. Abud Bakri
Video auditRetatrutide Masterclass (the 'how to' for EVERYTHING) - Dr Trevor Bachmeyer
Video auditSafety Concerns Over Doctors Prescribing an Experimental Weight-Loss Drug
Video auditI Almost Died From a Fake Weight-Loss Injection
Video auditCan Peptides Heal Your Joints, Gut, and Brain? Doctors Explain the Evidence
Video auditUnapproved Weight-Loss Drug Sparks Black-Market Concerns
ComparisonRetatrutide vs Tirzepatide
Evidence curationBest Peptides for Weight Loss
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.